Liping Liu, HighTide Therapeutics CEO

High­T­ide Ther­a­peu­tics rides NASH R&D wave with a $107M raise

High­T­ide Ther­a­peu­tics has raised a $107 mil­lion Se­ries C round to fund mid-stage stud­ies in meta­bol­ic and di­ges­tive dis­eases, with the goal of fil­ing for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.